Your browser doesn't support javascript.
loading
Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes.
Musacchio, Nicoletta; Zilich, Rita; Ponzani, Paola; Guaita, Giacomo; Giorda, Carlo; Heidbreder, Rebeca; Santin, Pierluigi; Di Cianni, Graziano.
Afiliação
  • Musacchio N; AMD past President - AMD AI National Group Coordinator, Milan, Italy.
  • Zilich R; Mix-x SRL, Ivrea, Italy.
  • Ponzani P; Diabetes and Endocrinology Unit, Local Health Autlhority 4 Chiavari, Chiavari, Italy.
  • Guaita G; Diabetes and Endocrinology Unit, ASL SULCIS, Iglesias, Italy.
  • Giorda C; Diabetes and Endocrinology Unit, ASL TO5, Chieri, Italy.
  • Heidbreder R; PsychResearchCenter, LLC, Powhatan, Virginia, USA.
  • Santin P; Deimos, Udine, Italy.
  • Di Cianni G; USL Tuscany Northwest Location Livorno, Diabetes and Metabolic Disease, Livorno, Italy.
J Diabetes ; 15(3): 224-236, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36889912
ABSTRACT

AIMS:

The objective of this study is to establish a predictive model using transparent machine learning (ML) to identify any drivers that characterize therapeutic inertia.

METHODS:

Data in the form of both descriptive and dynamic variables collected from electronic records of 1.5 million patients seen at clinics within the Italian Association of Medical Diabetologists between 2005-2019 were analyzed using logic learning machine (LLM), a "clear box" ML technique. Data were subjected to a first stage of modeling to allow ML to automatically select the most relevant factors related to inertia, and then four further modeling steps individuated key variables that discriminated the presence or absence of inertia.

RESULTS:

The LLM model revealed a key role for average glycated hemoglobin (HbA1c) threshold values correlated with the presence or absence of insulin therapeutic inertia with an accuracy of 0.79. The model indicated that a patient's dynamic rather than static glycemic profile has a greater effect on therapeutic inertia. Specifically, the difference in HbA1c between two consecutive visits, what we call the HbA1c gap, plays a crucial role. Namely, insulin therapeutic inertia is correlated with an HbA1c gap of <6.6 mmol/mol (0.6%), but not with an HbA1c gap of >11 mmol/mol (1.0%).

CONCLUSIONS:

The results reveal, for the first time, the interrelationship between a patient's glycemic trend defined by sequential HbA1c measurements and timely or delayed initiation of insulin therapy. The results further demonstrate that LLM can provide insight in support of evidence-based medicine using real world data.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article